Evolution of the Targeted Therapy Landscape for Cholangiocarcinoma: Is Cholangiocarcinoma the ‘NSCLC’ of GI Oncology?

SIMPLE SUMMARY: In the past 20 years, the development of targeted therapies that can be matched to a tumor’s molecular and immune abnormalities has resulted in the improvement of outcomes for patients suffering from advanced aggressive malignancies. Remarkably, non-small cell lung cancer (NSCLC) has...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Amol, Kurzrock, Razelle, Adashek, Jacob J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10000383/
https://www.ncbi.nlm.nih.gov/pubmed/36900367
http://dx.doi.org/10.3390/cancers15051578

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10000383/
https://www.ncbi.nlm.nih.gov/pubmed/36900367
http://dx.doi.org/10.3390/cancers15051578

Ejemplares similares